Drugs / LD rhIL-2
LD rhIL-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07161999 | Oct 2025 → Jan 2027 expected | amyotrophic lateral sclerosis | Coya Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LD rhIL-2 | “LD rhIL-2 and CTLA-4 Ig” NCT07161999 ↗ |
| Known as | LD IL-2 | “It is comprised of low dose interleukin-2 (LD IL-2) and DRL\_AB (a biosimilar candidate for abatacept).” NCT07161999 ↗ |
| Known as | low dose interleukin-2 | “It is comprised of low dose interleukin-2 (LD IL-2) and DRL\_AB (a biosimilar candidate for abatacept).” NCT07161999 ↗ |